GUIDANCE DOCUMENT
Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry Draft Guidance for Industry February 2022
Not for implementation. Contains non-binding recommendations.
This guidance is being distributed for comment purposes only.
Submit Comments by
Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment on a draft guidance before it begins work on the final version of the guidance, submit either online or written comments on the draft guidance before the close date.
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2021-N-0556
- Docket Number:
- FDA-2021-N-0556
- Issued by:
-
Guidance Issuing OfficeCenter for Drug Evaluation and Research
This guidance is written in response to the statutory requirements of section 3001(b) of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, which directs the Food and Drug Administration (FDA) to issue or update existing guidance to help address challenges to developing nonaddictive medical products to manage pain. In keeping with the mandate of section 3001(b), and considering the severity of the ongoing opioid crisis, this guidance is also intended to assist sponsors in the development of alternatives to opioids for the management of acute pain. Accordingly, this guidance addresses FDA’s current thinking about three specific topics: development of non-opioid analgesic products for acute pain, labeling claims, and expedited programs as they pertain to this purpose.